How to appeal a Highmark liver (non-hcv) — nash/mash, pbc, aih, wilson denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for liver (non-hcv) — nash/mash, pbc, aih, wilson

Cited policy: BCBS Specialty Pharmacy — IBAT inhibitors (Bylvay, Livmarli) for PFIC / Alagille

PFIC (Bylvay >=3 mo) or Alagille (Livmarli >=1 yr) genotype-confirmed. Pediatric hepatologist Rx.

How Highmark denies liver (non-hcv) — nash/mash, pbc, aih, wilson — and how to counter it

Where Highmark pushes back: 1) 'Pediatric/rare — needs specialist'; 2) Cost-prohibitive; 3) Off-label use.

Counter-arguments that hold up: Both FDA-approved for pediatric cholestatic pruritus (Bylvay Jul 2021 PFIC, Jun 2023 Alagille; Livmarli Sep 2021 Alagille, Mar 2024 PFIC). PEDFIC-1/2 + MARCH pivotal. Specialist letter from pediatric hepatologist. Orphan drug designation; no alternative IBAT inhibitor.

What Highmark typically denies for liver (non-hcv) — nash/mash, pbc, aih, wilson

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For liver (non-hcv) — nash/mash, pbc, aih, wilson, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the liver (non-hcv) — nash/mash, pbc, aih, wilson treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Rezdiffra (NASH)
• Ocaliva
• Iqirvo
• Livdelzi
• UDCA
• Xifaxan + lactulose

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.